January 12, 2018

January 12, 2018

Cure on Wheels bike-a-thon: Aubuchon to ride to support cancer research

Pine Island Eagle – Jan. 11
To prepare for the lengthy ride on Jan. 14 - roughly 325 miles- he tackles year round training on a spin bike about four days a week with his trainer, David Salko. Salko also will travel from the area to Moffitt Cancer Center where the ride begins.

Rare melanoma type highly responsive to immunotherapy

Medical Xpress – Jan. 11
However, Moffitt Cancer Center researchers report in the Jan. 10 issue of Nature that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed. Also posted to News-Medical.net, ecancer and European Pharmaceutical Review.

CAR T-cell therapies in treating lymphoma: Pros and cons

Managed Healthcare Executive – Jan. 10
(Fred Locke, MD, a medical oncologist at Moffitt Cancer Center, tells MHE that Kymriah (tisagenlecleucel) from Novartis costs $475,000, and Yescarta (axicabtagene ciloleucel) from Gilead costs $373,000.)

Venture capital invests big in Tampa metro companies in 2017

Tampa Bay Business Journal – Jan. 9
In the Tampa metro, M2Gen, the Moffitt Cancer Center subsidiary that uses big data to find ways to treat cancer, had the single largest deal of 2017, a $75 million investment from Hearst, a diversified media, information and services company. 

Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia

Drugs.com – Jan. 9
“Approximately half of new ALL cases occur in adults age 20 or older and a majority of adult ALL patients relapse and have poor subsequent outcomes,” said Bijal Shah, MD, ZUMA-3 investigator and medical oncologist, Moffitt Cancer Center, Tampa, Fla.

Positive Results From a Multi-Center Analysis of Delcath PHP Therapy Published in Journal of Surgical Oncology

Markets Insider – Jan. 9
The study, Percutaneous Hepatic Perfusion with Melphalan in Uveal Melanoma: A Safe and Effective Treatment Modality in an Orphan Disease, was conducted by researchers from Moffitt Cancer Center (Moffitt) in Tampa, FL and the University Hospital Southampton (UHS) in the United Kingdom. 

Evolution and cancer take center stage at ISEEC conference

Arizona State University – Jan. 9
(Gatenby is an MD who studies the evolutionary dynamics of drug resistance in cancer at Florida’s Moffitt Cancer Center.)

Teen nonprofit serves area causes

Tampa Bay Times – Jan. 9
Campbell and her friends generated lots of needed smiles at the Benjamin Mendick Hope Lodge, an American Cancer Society organization that provides temporary housing to cancer patients treated at Moffitt Cancer Center and other area facilities.

Moody's affirms 'A3' rating on H. Lee Moffitt Cancer Center

Becker’s Hospital Review – Jan. 8
Moody's Investors Service affirmed its "A3" rating on Tampa, Fla.-based H. Lee Moffitt Cancer Center's bonds, affecting $131 million of debt.

Jon Gruden Biography

Raiders.com – Jan. 6
In 2015, the Moffitt Cancer Center dedicated the Gruden Huddle Room at the Moffitt McKinley Outpatient Center in Tampa in recognition of the Gruden family’s support.

Cancer researchers learn more about toxic side effects

Daily Herald – Jan. 6
That review was based on 100 patients treated at MD Anderson, Moffitt Cancer Center in Tampa, the Sylvester Cancer Center at the University of Miami and the Mayo Clinic Cancer Center in Rochester, Minnesota.

Local legislators file several bills as session begins

Lakeland Ledger – Jan. 6
House Bill 4393: Rep. Mike La Rosa, R-St. Cloud, filed a bill that would provide $1.7 million to the Department of Health to fund the Moffitt Cancer Center-Coalition for Medical Cannabis Research and Education.

Faced with cancer battle, Brandon resident sounded her trumpet

Tampa Bay Times – Jan. 5
One year, three surgeries, and four grueling rounds of chemotherapy later, the doctors at Moffitt Cancer Center declared me to be free of disease — the invasion had been stopped in its tracks.

Moody's affirms H. Lee Moffitt Cancer Center's A3; outlook stable

Moody’s Investors Service – Jan. 5
Lee Moffitt Cancer Center (Moffitt) benefits from good market position and brand penetration, as evidenced by health revenue growth, strong debt measures and long history of State support. 



Please note we cannot guarantee the accuracy or availability of links. The stories belong to the respective publishers, and links may expire. Some news sites require you to register and select a password in order to retrieve articles, but most usually do not charge a fee to retrieve these news stories.